Clinical trials: Carcinoma Breast
Lymphedema, Breast Cancer
The 24 Hour Effects of Remedial Exercises With and Without Compression Therapy on Breast Cancer-related Lymphedema
The aim of this study to investigate 24 hours of effects of remedial exercises with and without compression therapy on severity of lymphedema and symptoms of the lymphedema The present study is designed as a non-drug clinical…
- Trial name
- NCT05610579
- Testing
- Remedial exercise, Compression bandage
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Hacettepe University
Breast Cancer
De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You
This is a live biobank study for breast cancer (BC) patients where samples will be collected at inflection points in the course of the disease.
- Trial name
- DIGNITY (NCT05134779)
- Testing
- Live Biobank
- Where
- 2 sites in United States
- Volunteers
- 400 people
- Sponsor
- Weill Medical College of Cornell University
Breast Cancer
Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation
This pilot study will evaluate the feasibility of at least twice daily use of azelaic acid in breast cancer patients undergoing radiation treatment.
- Trial name
- NCT06966388
- Testing
- Azelaic Acid
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Virginia Commonwealth University
Breast Cancer, Complementary Therapies
Supportive Effects of Craniosacral Therapy for Women With Breast Cancer
Craniosacral Therapy (CST) is a non-manipulative, very gentle, manual treatment method that aims to release restrictions of the fasciae and regulate the arousal of the sympathetic nervous system, which is often increased in…
- Trial name
- CRANIO4US (NCT04319510)
- Testing
- Craniosacral therapy, Craniosacral self-help group training, Treatment as usal / wait list
- Where
- 3 sites in Germany
- Volunteers
- 102 people
- Sponsor
- Universität Duisburg-Essen
Triple Negative Breast Cancers Without Lymph-node Involvement and < or = 30 mm
Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm
This is a prospective, non-randomized and multicenter study designed to compare biological features between pN0 triple negative breast cancer (TNBC) with size ≤ 10 mm (pT1a/b) versus pT1c T2 ≤ 30 mm.
- Trial name
- COCABIO000 (NCT02266420)
- Testing
- Blood samples of 10 mL
- Where
- 11 sites in France
- Volunteers
- 151 people
- Sponsor
- Institut Claudius Regaud
Breast Neoplasms, Neoplasm Metastasis
A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer
The goal of this phase 1 open label clinical trial is to evaluate the safety and preliminary efficacy of CodaLytic, an intratumorally-administered oncolytic virus, in patients with metastatic or otherwise inoperable breast…
- Trial name
- NCT05600582
- Testing
- CodaLytic
- Where
- 2 sites in United States
- Sponsor
- Codagenix, Inc
Trastuzumab-rezetecan, HER2-low Breast Cancer
Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer
This study is a multicenter, observational, real-world investigation. The research plans to enroll 300 HER2-positive and HER2-low breast cancer patients who meet the inclusion criteria.
- Conditions
- Trastuzumab-rezetecan, HER2-low Breast Cancer, HER2-positive Breast Cancer
- Trial name
- NCT07358182
- Testing
- Trastuzumab-rezetecan Treatment Group
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Breast Cancer, Axillary Lymphadenitis
Evaluation of a Novel Axillary Lymph Node Ink Localization Technique: A Feasibility Study
Patients with breast cancer and metastatic axillary lymphadenopathy routinely undergo neo-adjuvant chemotherapy. For these patients, biopsy clip markers are inserted into the biopsy proven metastatic lymph node pre-treatment, as…
- Trial name
- NCT04136496
- Testing
- Black-Eye Ink
- Where
- Canada
- Sponsor
- The Ottawa Hospital
Breast Cancer Female
Personalized Vaccine for Cancer Immunotherapy
Due to their genetic instability, breast tumors that do not express receptors for Estrogens, Progestagens or amplify the Her2 / neu oncogene [called triple-negative breast cancer (TNTC)] and other tumors such as melanoma…
- Trial name
- NCT04879888
- Testing
- Peptide pulsed Dendritic cell
- Where
- Colombia
- Volunteers
- 9 people
- Sponsor
- Universidad Nacional de Colombia
Breast Neoplasm Female
Breast PET Feasibility
Breast PET may be able to help in the diagnostic pathway in patients to determine which ones need to go on to have a second look ultrasound +/- biopsy and those who need to be sent for MRI guided biopsy.
- Trial name
- Breast PET (NCT03198442)
- Testing
- F-18 FDG breast PET scan
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University College, London
Cancer Survivor, Central Obesity
Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer
This randomized phase II trial studies how well exercise intervention works in targeting adiposity and inflammation with movement to improve prognosis in stage I-III breast cancer survivors.
- Conditions
- Cancer Survivor, Central Obesity, Estrogen Receptor Positive, Postmenopausal
- Trial name
- NCT03091842
- Testing
- Exercise Intervention, Informational Intervention, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- University of Southern California
Metastatic Breast Cancer
Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
This is a multicenter, open-label, single-arm Phase II study designed to evaluate the effect of T-DM1 on the duration of corrected QT (QTc) interval in patients with HER2-positive locally advanced or metastatic breast cancer and…
- Trial name
- NCT00943670
- Testing
- pertuzumab, Trastuzumab emtansine [Kadcyla]
- Volunteers
- 51 people
- Sponsor
- Genentech, Inc.
HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy
This trial is a combination of trastuzumab and pyrotinib in the treatment of patients with HER2-positive metastatic breast cancer who have progressed on TKI therapy. A total of 50 patients were enrolled in the study design.
- Trial name
- NCT05560308
- Testing
- Trastuzumab Emtansine for Injection, Pyrotinib Maleate Tablets
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Breast Cancer, Female Breast Cancer
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
This is a multicenter, randomized, double-blind, placebo-controlled Phase iii clinical study evaluating the efficacy and safety of FCN- 437c in combination with fluvestrant ± goseraline versus placebo in combination with…
- Trial name
- NCT05438810
- Testing
- FCN-437c,Fulvestrant,Goserelin acetate
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Ahon Pharmaceutical Co., Ltd.
Breast Neoplasm
Feasibility Study of Stereotactic Body Radiotherapy for Early Breast Cancer
Most women with early breast cancer are treated with breast conserving therapy (BCT), consisting of breast conserving surgery (surgery to remove the cancer itself) followed by radiation to the breast.
- Trial name
- ARTEMIS (NCT02065960)
- Testing
- Stereotactic body radiotherapy (SBRT)
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- Juravinski Cancer Center
Breast Cancer Survivor
The INFLUENCE of PHYSICAL ACTIVITY on the HEALTH and WELL-BEING of BREAST CANCER SURVIVORS
Introduction: Cancer remains a leading cause of death globally, with breast cancer being the most common type among women worldwide. The risk of breast cancer is influenced by genetic and lifestyle factors.
- Trial name
- PAF-SBM (NCT06672380)
- Testing
- Remote Physical Exercise Program for Breast Cancer Survivors, Initial Consultation and Exercise Guidance via Ebook for Women Surviving Breast Cance, Initial Incentive for Eating Habits in Women Surviving Breast Cancer
- Where
- Brazil
- Volunteers
- 32 people
- Sponsor
- Federal University of Bahia
Breast Cancer
Acute Exercise Cardioprotection From Doxorubicin
In rodents, a single bout of exercise prior to injection of a chemotherapy agent used to treat breast cancer prevents or attenuates a number of markers of cardiac injury.
- Trial name
- NCT02006979
- Testing
- exercise
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- University of British Columbia
Breast Cancer, Prostate Cancer
Adherence to Oral Therapies in Advanced Breast and Prostate Cancers
AdOTAC is a pilot study, open, prospective, single-center, one-arm. The 200 patients will be included. Patient is included at Day 0.
- Trial name
- AdOTAC (NCT06435546)
- Testing
- Blood samples, Adherence to anti-cancer therapies questionnaires
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut de Cancérologie de Lorraine
Breast Cancer Prevention
MELIORA Virtual Coach Intervention for Breast Cancer Prevention
Breast cancer (BC) is the most commonly diagnosed cancer in women worldwide, with early-onset cases increasing due to genetic and lifestyle factors.
- Trial name
- MELIORA (NCT07200427)
- Testing
- MELIORA Virtual Coach Intervention, Control (generic advice)
- Where
- 7 sites in Greece, Lithuania and 2 more
- Volunteers
- 2,080 people, healthy volunteers welcome
- Sponsor
- Harokopio University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.